SCHEMBL6340500

SCHEMBL6340500

Cc1cc(Cl)cc2c1OCCCC2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 6/20 0.36
CES1 P23141 1/20 0.36
PDE4A P27815 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PGR P06401 1/20 0.34
BRD4 O60885 3/20 0.33
NOTUM Q6P988 1/20 0.32
VHL P40337 1/20 0.32
ELOC Q15369 1/20 0.32
ELOB Q15370 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
BRDT Q58F21 1/20 0.32
CREBBP Q92793 1/20 0.32
CECR2 Q9BXF3 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
BRD7 Q9NPI1 1/20 0.32
BAZ2B Q9UIF8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6582453 0.90 SIRT2 (0.38) SIRT2CES1MEN1KMT2AL3MBTL1
SCHEMBL13534195 0.76 NOTUM (0.38) PDE4ANOTUM
SCHEMBL11747003 0.74 BRD4 (0.43) CES1MEN1KMT2AL3MBTL1BRD4
SCHEMBL67615 0.73 MEN1 (0.46) SIRT2CES1MEN1KMT2AL3MBTL1
SCHEMBL11352770 0.73 SIRT2 (0.43) SIRT2KMT2A
SCHEMBL30543406 0.73 MEN1 (0.46) SIRT2CES1MEN1KMT2AL3MBTL1
SCHEMBL1181902 0.70 CTSL (0.46) NOTUMVHLELOCELOB
SCHEMBL14053377 0.70 NOTUM (0.42) SIRT2PDE4AMEN1KMT2AL3MBTL1
SCHEMBL12316699 0.70 LMNA (0.42) SIRT2MEN1KMT2AL3MBTL1VHL
SCHEMBL8191575 0.70 MAOB (0.37) SIRT2MEN1KMT2AL3MBTL1VHL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908947-B2 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-21 US disclosed
EP-0861836-B1 Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity AVENTIS PHARMA GMBH (DE) 2004-12-29 EP disclosed
US-20020072514-A1 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them HOECHST AKTIENGESELLSCHAFT 2002-06-13 US disclosed
US-6333349-B1 POTASSIUM CHANNEL OR THE I.SUB.KS CHANNEL OPENED BY CYCLIC ADENOSINE MONOPHOSPHATE AS POTASSIUM CHANNEL ACTIVATORS AND CARDIOVASCULAR DISORDERS, ANTIARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL REGION OR FOR THE TREATMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-25 US disclosed
EP-0861836-A1 Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity HOECHST AKTIENGESELLSCHAFT (DE) 1998-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072514-A1 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them KCNN3, KCNJ1, KCNJ11 SIRT2 2055/4885CES1 2325/4885PDE4A 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.